Section of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
Children's Healthcare of Atlanta, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA.
Blood Adv. 2021 Sep 14;5(17):3457-3467. doi: 10.1182/bloodadvances.2021004287.
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by pathologic immune activation in which prompt recognition and initiation of immune suppression is essential for survival. Children with HLH have many overlapping clinical features with critically ill children with sepsis and systemic inflammatory response syndrome (SIRS) in whom alternative therapies are indicated. To determine whether plasma biomarkers could differentiate HLH from other inflammatory conditions and to better define a core inflammatory signature of HLH, concentrations of inflammatory plasma proteins were compared in 40 patients with HLH to 47 pediatric patients with severe sepsis or SIRS. Fifteen of 135 analytes were significantly different in HLH plasma compared with SIRS/sepsis, including increased interferon-γ (IFN-γ)-regulated chemokines CXCL9, CXCL10, and CXCL11. Furthermore, a 2-analyte plasma protein classifier including CXCL9 and interleukin-6 was able to differentiate HLH from SIRS/sepsis. Gene expression in CD8+ T cells and activated monocytes from blood were also enriched for IFN-γ pathway signatures in peripheral blood cells from patients with HLH compared with SIRS/sepsis. This study identifies differential expression of inflammatory proteins as a diagnostic strategy to identify critically ill children with HLH, and comprehensive unbiased analysis of inflammatory plasma proteins and global gene expression demonstrates that IFN-γ signaling is uniquely elevated in HLH. In addition to demonstrating the ability of diagnostic criteria for HLH and sepsis or SIRS to identify groups with distinct inflammatory patterns, results from this study support the potential for prospective evaluation of inflammatory biomarkers to aid in diagnosis of and optimizing therapeutic strategies for children with distinctive hyperinflammatory syndromes.
噬血细胞性淋巴组织细胞增生症(HLH)是一种以病理性免疫激活为特征的综合征,迅速识别和启动免疫抑制对于生存至关重要。患有 HLH 的儿童与患有败血症和全身炎症反应综合征(SIRS)的危重症儿童有许多重叠的临床特征,在这些儿童中需要采用替代疗法。为了确定血浆生物标志物是否可以将 HLH 与其他炎症情况区分开来,并更好地定义 HLH 的核心炎症特征,我们比较了 40 例 HLH 患者和 47 例严重败血症或 SIRS 儿科患者的炎症性血浆蛋白浓度。与 SIRS/败血症相比,HLH 血浆中有 135 种分析物中的 15 种明显不同,包括干扰素-γ(IFN-γ)调节的趋化因子 CXCL9、CXCL10 和 CXCL11 增加。此外,包括 CXCL9 和白细胞介素-6 在内的 2 种血浆蛋白分类器能够将 HLH 与 SIRS/败血症区分开来。与 SIRS/败血症相比,血液中 CD8+T 细胞和激活的单核细胞中的基因表达在外周血单个核细胞中也富含 IFN-γ 通路特征。本研究确定了炎症蛋白的差异表达作为识别患有 HLH 的危重症儿童的诊断策略,对炎症性血浆蛋白和全基因组表达的全面无偏分析表明,IFN-γ 信号在 HLH 中是独特升高的。除了证明 HLH 和败血症或 SIRS 的诊断标准能够识别具有不同炎症模式的组之外,这项研究的结果还支持对炎症生物标志物进行前瞻性评估以辅助诊断和优化具有独特高炎症综合征的儿童的治疗策略的潜力。